

# **Recurrent Miscarriage Guideline 2017**

# **Referral Criteria and Investigation**

#### **Scope**

This guideline provides guidance on the diagnosis and care of women who experience recurrent consecutive first trimester miscarriages and/or second trimester losses within NHS Lanarkshire.

#### **Definition**

Women are classified as experiencing recurrent early pregnancy loss (REPL) if they have had three or more consecutive losses prior to 12+0 weeks' gestation of a clinically confirmed potentially viable pregnancy.

Women are classified as having had a second trimester loss if they have had a pregnancy loss of a clinically confirmed, potentially viable pregnancy of a confirmed gestation between 12+0-23+6 weeks. Two confirmed second trimester losses also fulfil the criteria for REPL.

#### **Criteria for Referral**

- Women who have experienced 3 or more consecutive pregnancy losses prior to 12+0 weeks'
  gestation of clinically confirmed potentially viable pregnancies are eligible for referral to the
  REPL clinic. (seen on scan, intrauterine, confirmed products of conception)
- Women who have experienced 2 or more pregnancy losses between 12+0 and 23+6 weeks' gestation of a potentially clinically viable pregnancy are eligible for referral to the REPL clinic.
- Women aged > 38 years who have experienced 2 or more consecutive miscarriages of clinically confirmed potentially viable pregnancies are eligible for referral to the REPL clinic.
- Women who have had 3 or more pregnancy losses where clinical confirmation of potential viability cannot be confirmed for one or more loss may be considered for review at the MOT clinic on a case-by case basis.
- Women with a confirmed diagnosis of REPL should be referred to the REPL clinic at WGH or
   MOT clinic depending on the background and investigations to date
- Do not promise women that a REPL appointment will be sent as if the criteria are not met they will not be appointed.
  - o The REPL/MOT staff are always available to discuss referrals

#### **Exclusion criteria**

The following pregnancy outcomes should not be included when assessing for REPL:

- Ectopic pregnancy
- Pregnancy of unknown location/biochemical
  - o 40-80% of conceptions: Reassurance is sufficient
- Molar pregnancy
- Unsuccessful IVF (no FH seen)
- Termination of pregnancy for social or medical reasons

#### **Associated Causes**

#### **Thrombophilias**

<u>Acquired</u> – This is predominantly related to Antiphospholipid syndrome (APS). This affects 15% of women who present with recurrent miscarriage.

- We test for **significantly elevated** anticardiolipin antibodies (aCL) and/or a positive Lupus Anticoagulant.
- Two positive tests taken at least 12 weeks apart are required.
- After the first positive test, <u>advise the woman to use effective contraception until it has</u>
   <u>been repeated</u>. Falling pregnant before investigations are complete complicate the
   diagnosis and management

APAS is also diagnosed when the following is present:

- either clinical thrombosis (arterial or venous),
- 1 or more pregnancy losses >10 weeks of a morphologically normal infant,
- 1 or more preterm birth <34 weeks due to pre-eclampsia or
- 3 or more miscarriages <10 weeks where no other cause is identified...

<u>Inherited</u> – These include Factor V Leiden, Protein C and S deficiencies.

- These are weakly associated with recurrent miscarriage.
- Factor V Leiden and Prothrombin G20210A mutation may be associated with an increased risk of late second trimester loss.
- Antithrombin, Protein S or Protein C deficiency may also be associated with pregnancy loss typically in the third trimester.

#### **Genetic Causes**

- We no longer routinely test for parental karyotype
  - We have an agreement with the WOS Genetic Services that products of conception from the third and later confirmed pregnancy losses, be sent dry with the correct paperwork for Chromosomal Analysis. (Page 7)
  - o The subsequent report will inform further investigation if necessary
- Approximately 2% of couples will demonstrate a chromosomal rearrangement that may result in unbalanced translocations in pregnancy.
- Inheritance and consequences of unbalanced chromosomes will depend on the chromosomes involved and the size of unbalanced information
  - Referral to Clinical Genetics is recommended when inheritance is confirmed
- The presence of pregnancy loss in association with aneuploidy increases the overall risk of future aneuploidy including fetal loss and may influence future pregnancy first trimester screening results.
- 70% of **sporadic** first trimester loss are due to chromosomal abnormalities.

#### Maternal uterine causes

- <u>Congenital</u> The most common congenital association with recurrent miscarriage is septate uterus. Other congenital uterine abnormalities include bicorunate, subseptate, unicorunate and didelphys uteri.
  - We currently do not recommend imaging beyond a pelvic ultrasound
    - Any anomalies should be reported when scanned at EPAS
    - If the uterus is normal at EPAS scanning, further imaging is not recommended.
  - Surgery has variable success and can increase risk of obstetric complications such as accreta.
- Acquired conditions Cervical Incompetence and Uterine Fibroids/Polyps.
  - Women who have an identified fibroid or polyp that encroaches on the uterine cavity may be associated with recurrent miscarriage.
  - Women with a history of late miscarriage (12-24 weeks) and early preterm deliveries or those with previous cervical trauma ( > 1 LLETZ, cone biopsies or unrepaired cervical lacerations) may be at risk of recurrent late miscarriage.

#### **Endocrine disorders**

- Hypothyroidism
  - Subclinical hypothyroidism and untreated clinical hypothyroidism have been implicated in recurrent miscarriage; however their relevance and potential therapies for subclinical hypothyroidism are yet to be confirmed.
  - We do not recommend thyroid function tests unless there are clinical features
- Polycystic Ovarian Syndrome
  - there is no clear causal relationship between PCOS and recurrent miscarriage, however there may be some association. There is currently no indicated treatment for this.
  - o Testing for PCOS is not recommended in the context of REPL
- Hyperprolactinaemia
  - Significantly elevated prolactin levels are weakly associated with reduced female fertility and miscarriage.
  - o Currently testing for prolactin is not recommended

#### Immune-related

- Recurrent miscarriage has been associated with a variety of variations in immune function.
- The theoretical association of rejection of pregnancy tissue by the maternal immune system has yet to be proven.
- There may be an association with activation of peripheral and /or uterine natural killer cells. At present there is no standardised test to identify these as a potential cause. Research is ongoing to identify normal values and possible therapies where elevated NK/uNK cells have been implicated in recurrent pregnancy loss.
  - o We do not recommend referral for such testing

#### **Infections**

- Pelvic infections are associated with single miscarriages, however in the event of treated diseases, no clear link has been established with recurrent miscarriage.
  - Bacteriological testing is not indicated in the context of REPL

## **Environmental factors**

- Smoking, alcohol consumption, a high BMI and illicit substance use are all associated with pregnancy loss.
  - We recommend complete cessation of smoking
  - We recommend avoidance of alcohol
  - We recommend a healthy diet , prenatal folic acid and strongly advise a normal BMI

## Unexplained

• Despite these categories, there remain a significant proportion of women where a cause is not demonstrated.

### **Investigations**

Women who attend the REPL/MOT clinic will undergo:

- Full blood count
- Antiphospholipid antibody tests (Anticardiolipin/ Lupus Anticoagulant)
- Thrombophilia screening
- TFTs (if clinical features only)
- RBG and HbA1c if there is a history of diabetes
- If tissue is available, karyotyping should be offered of pregnancy tissue after 3<sup>rd</sup> and subsequent consecutive miscarriages.
- Consideration will be given to parental karyotyping if no pregnancy tissue is available, but a
  pregnancy was seen on ultrasound on the third confirmed loss
  - This information must be included in the request form, or it may be declined
- Parents with demonstrated translocations etc, should be referred to clinical genetics
- Women with previous aneuploidy will be offered routine first trimester screening
- Ultrasound at EPAS should be report any suspected uterine anomalies.
- Women with two previous LLETZ, one or more cone biopsies or a history of recurrent late miscarriage should undergo serial cervical scans in subsequent pregnancies.

#### **Treatments**

- Women who have a diagnosis of Antiphospholipid syndrome should therefore be prescribed
   LDA and LMWH in all future pregnancies, once there are no contraindications.
- There is limited evidence of benefit with the use of LMWH in women with inherited thrombophilias.
  - o Refer to MOT clinic for counselling
  - o Their use may be indicated for thromboprophylaxis for the mother.
- Women who have a diagnosis of an inherited thrombophilia should be assessed regarding their thromboembolic risk and LMWH given if indicated to reduce the risk of venous thromboembolism at the appropriate gestation (Green top Guideline 37a 2015)
- There is limited evidence of a benefit to **progesterone** administration for women with unexplained recurrent miscarriage.
  - The PROMISE trial gave a clear result in that women who received progesterone where no less likely to miscarry than those who received placebo
  - We do not routinely recommend progesterone treatment
- Prednisolone is at present being assessed for efficacy in treatment of women considered to have elevated natural killer cells.
  - At present there is no standardised protocol for their use and is restricted to administration within the confines of research.
- Intravenous Immunoglobulins (IVIG)
  - Women should be advised that at present there is very little evidence of benefit of the use of IVIG in unexplained miscarriage and there are no clear clinical indications for its use outside of a research context.
  - o Use of IVIG is therefore not currently supported.

### • Pre-implantation Genetic Diagnosis and IVF

- This can be considered on a case by case basis and only after genetic counselling has been completed when there is a parental chromosomal abnormality
- o The recurrence risk depends on nature of chromosomal abnormality.
- Those with demonstrated uterine anomalies should be aware that at present, there is little
  evidence to suggest that surgical correction improves live birth rate. Consideration for
  surgical intervention should therefore be reserved for case-by-case recommendation.
- Women with a shortened cervix (<15 mm) may be considered for cervical cerclage.</li>
   Progesterone has not been shown to be of clear benefit
- All women and their partners should be counselled about smoking cessation. Women should be advised to avoid alcohol consumption while trying for a pregnancy. Women who have an ongoing history of substance misuse should be referred to LAMS.
- A healthy BMI improves outcome

### **GENETICS TEST REQUEST FORM**

West of Scotland Genetic Services (Laboratories)
Level 2, Laboratory Medicine, Southern General Hospital, Govan Road, Glasgow, G51 4TF
<a href="http://www.nhsqqc.org.uk/medicaiqenetics">http://www.nhsqqc.org.uk/medicaiqenetics</a>



ENQUIRIES Tel: 0141 354 9300 Fax: 0141 232 7980 Email: geneticlabs@ggc.scot.nhs.uk

Family name:   First name(s):	DATIFUT DETAILS (D. L. J.L. J.Z Y.L.)	DECEMBED DETAIL &
Farning name.   First name(s):   DOB:   Sex:   M   F   U	PATIENT DETAILS (Printed label if available)	REFERRER DETAILS
First name(s):  DOB: Sex: M   F   U    CHI number: Tel (mandatory) Address:  Postoode: Pedigree/ your ref. Hospital Number:  Postoode: Pedigree/ your ref. Hospital Number:  REASON FOR REFERRAL/CLINICAL INDICATION Is the patient dinically affected? Y   N   Is the patient dinically affected? Y   N   Is there a family history (if yes, give details)? Y   N   Is there a family history (if yes, give details)? Y   N    Is there a family history (if yes, give details)? Y   N    Is the patient of minimal yaffected?   N   Is the patient of minimal yaffected?   N   Is the patient pregnant? Y   N   Is the patient pregnant? Y   N   Is the patient pregnant? Y   N   If yes, how many weeks gestation?   Weeks    SAMPLE REQUIRED    Doevelopmental delay   Blood LiHep + EDTA   Chromosomes/karyotype   Cincluding Qi-PCR)    Prenatal diagnosis   CVS/AF   (please circle)    SAMPLE REQUIREMENT :  Bleep: Dota: Time:   HIGH RISK   URGENT    SAMPLE REQUIREMENT :  EDTA and LiMium Hisparia blood: Smil adulticitizine, fmil neonates (EDTA), Zmil neonates (LHep). Invert tubes several times to prevent cicting.  Ambide Riad (AP) two separates teric universal bloes, 15mil for cultrue plus 5mil for qi-PCR (samples for qi-PCR must arrive before 2pmi. Transport needia svalidate from laboratory. Planting least or container. Times are higher and refersed containers to minimal passes that arrive in the laboratory padres for prevent cicting.  The sample and referred card whole he sealed separately in a blockard page review contamination in the event of a leastage. Minimal page review contamination in the event of a leastage. Minimal page review contamination in the event of a leastage. Minimal page review contamination in the event of a leastage. Minimal page review contamination in the event of a leastage. Minimal page review contamination in the event of a leastage. Minimal page review contamination in the event of a l	Family name:	
OB: Sex: M   F   U    CHI number: (mandatory) Address:  Pedigree/ Postcode: Pedigree/ your ref: Hospital Number: Hospital Number:  REASON FOR REFERRAL/ CLINICAL INDICATION Is the patient clinically affected? Is there a family history (if yes, give details)? Y   N   Is there a family history (if yes, give details)? Y   N   DNA analysis (may require clinical genetics approval)  DNA extraction and storage   Blood EDTA   Biochemical genetics approval)  DNA extraction and storage   Blood EDTA   Biochemical genetics approval)  Is the patient pregnant? Y   N   If yes, how many weeks gestation?   weeks    SAMPLING DETAILS  Taken by: Bleep: Date: Time:  HIGH RISK   URGENT    SAMPLING DETAILS  Taken by: Bleep: Date: Time:  HIGH RISK   URGENT    DAMPLING DETAILS  TAKEN BLOOK Smill adults/children, fini neonates (EDTA). Zmi neonates (LiHep). Invert tubes several times to prevent cioting. Amaiola full (AP): too separate settle environment butes, 15mi for culture plus Smi for 47-POR insure traces before 2 pm.  TAMPLER EQUIREMENT?:  EDTA and LiMbium Hispario blood: Smi adults/children, fini neonates (EDTA). Zmi neonates (LiHep). Invert tubes several times to prevent cioting. Charlons will (EVS): 10-Juling in steric transport media svalidate from laboratory. Final reads of container. Timour and frymph nodes should are the laboratory bard with earlier to relate some container. Timour and frymph nodes should are the laboratory bard with earlier to relate some passes of the shows 2 pm.  The sample and referred card and whole the sealed separation in a should be saided separation for a shadage. All the shadage and referred containers to microard containers. Timour and symph nodes the did sever to the laboratory. Final reads container. Timour and symph nodes the did sever to the laboratory. Final reads a container. Timour and symph nodes the did store to present container. Timour and symph nodes the did store to present to interest to the shadage. All the shadage and t	First name/s):	
Tel No: Fax No: Email:  CONSENT: R is the referring clinician's responsibility to obtain informed consent from the patient/carer for the test and for sample storage for any future diagnostic test.  Clinicians Signature:  Print Name:  REASON FOR REFERRAL/CLINICAL INDICATION Is the patient clinically affected? Is there a family history (if yes, give details)? Y   N    Is there a family history (if yes, give details)? Y   N    Is there a family history (if yes, give details)? Y   N    Is the patient pregnant?   Blood EDTA    Microarray (may require   Blood EDTA    Microarray (may require   Blood EDTA    Microarray (may require   Blood LiHep + EDTA    Chromosomes/karyctype   Blood LiHep + EDTA    Chromosome	Tist harre(s).	for report:
No: Fax No: Email:   CONSENT: It is the referring clinician's responsibility to obtain informed consent from the patient/loarer for the test and for sample storage for any future diagnostic test.	DOB: Sex: M ☐ F ☐ U ☐	
No.   Fax No.	CHI number:	Tel
Postoode: Pedigree/ your ref: Hospital Number:  REASON FOR REFERRAL CLINICAL INDICATION Is the patient dinically affected? Y N D DNA analysis (may require clinical genetics approval) DNA analysis (may require clinical genetics approval) DNA extraction and storage Blood EDTA  Bis there a family history (if yes, give details)? Y N D DNA extraction and storage Blood EDTA  Biochemical genetics approval) DNA extraction and storage Blood EDTA  Biochemical genetics approval) DNA extraction and storage Blood EDTA  Biochemical genetics approval) Blood LiHep + EDTA  Chromosomes/karyotype Blood LiHep + EDTA  Chromosomes/karyotype Blood LiHep + EDTA  Chromosomes/karyotype Prenatal diagnosis (rolling QF-PCR)  Frenatal diagnosis CVS/AF (please circle)  SAMPLING DETAILS  Taken by: Bleep: Date: Time: HIGH RISK URGENT D  SPECIMEN CONTAINER MUST BE LABELLED WITH TWO PATIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED  SAMPLE REQUIREMENTS: EDTA and Lithium Megantin blood: Smi adultsichidren, imi neonates (EDTA). Zmi neonates (LiHep), linvert tubes several times to prevent cioting. Annihold field (RY): the separates sterie unihersal tube container. Tumour and lymph nodes: should army to the laboratory. Solid ideaue: place sectionen in a sterie universal tube container. Tumour and lymph nodes: should army to the laboratory. Plantally eventume and supplied for any stance poor to the substance of the laboratory. Plantally eventume and supplied the laboratory. Plantally eventuments in biobaratory. Plantally eventuments are laboratory. Plantally eventuments in biobaratory. Plantally eventuments are laboratory. Plantally eventuments in biobaratory. Plantally eventuments are laboratory. Plantally eventuments in biobaratory.	. 27	
Dostoode: Pedigree/ your ref.	Address:	Email:
Dostoode: Pedigree/ your ref.		CONSENT: It is the referring clinician's responsibility to
Clinicians Signature:		
Clinicians Signature:   Print Name:	Postcodo: Pedigree/	and for sample storage for any future diagnostic test.
Print Name:	your ref:	Clinicians Signature:
REASON FOR REFERRAL/ CLINICAL INDICATION   Is the patient clinically affected?	Hospital Number:	
Is the patient clinically affected?  Is there a family history (if yes, give details)?  Y   N    DNA analysis (may require clinical genetics approval)  DNA extraction and storage   Blood EDTA    Biochemical genetics   Blood EDTA    Biochemical genetics   Blood EDTA    Biochemical genetics   Blood EDTA    Biochemical genetics   Blood LiHep + EDTA    Microarray (may require clinical genetics approval)   Blood LiHep + EDTA    Chromosomes/karyotype   Clinical genetics    If yes, how many weeks gestation?  SAMPLING DETAILS  Taken by: Bleep:  Date: Time:    HIGH RISK   URGENT    SPECIMEN CONTAINER MUST BE LABELLED WITH TWO PATIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED    SAMPLE REQUIREMENTS:    BAMPLE REQUIREMENTS:    SOTA and Lithlum Heparin blood: Smi adults/children, 1ml neonates (EDTA), 2ml neonates (LiHep), linvert tubes several times to prevent clotting. Amniboti fluid (AP): two separate sterile universal tubes, 15ml for culture plus 5ml for QF-PCR (samples for QF-PCR must arrive before 2pm. Transport media available from laboratory. Solid tissue: place specimen in a sterile universal tubes, 15ml for culture plus 5ml for QF-PCR (samples for QF-PCR must arrive before 2pm. Transport media available from laboratory. Solid tissue: place specimen in a sterile universal tube. 15ml for culture plus 5ml for QF-PCR must arrive before 2pm. Transport media available from laboratory. Solid tissue: place specimen in a sterile universal tube. 15ml for culture plus 5ml for devent of a row early for the please cortact the laboratory. Fixative (e.g. formalin) should NOT be added to any tissue, PCG or tumour specimens. Transport media available from laboratory. Fixative (e.g. formalin) should NOT be added to any tissue, PCG or tumour specimens. Transport media available from laboratory. Fixative (e.g. formalin) should NOT be added to any tissue, PCG or tumour specimens. Transport media ava	,	Frint Name.
Is there a family history (if yes, give details)? Y N DNA analysis (may require clinical genetics approval)  DNA extraction and storage Blood EDTA  Biochemical genetics Blood EDTA  Biochemical genetics Blood EDTA  Microarray (may require clinical genetics Blood LiHep + EDTA  Microarray (may require clinical genetics approval) Blood LiHep + EDTA  Chromosomes/karyotype (including QF-PCR)  Prenatal diagnosis CVS/AF (please circle)  SAMPLING DETAILS  Taken by: Bleep: Date: Time:  HIGH RISK URGENT DOTAINER MUST BE LABELLED WITH TWO PATIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED  SPECIMEN CONTAINER MUST BE LABELLED WITH TWO PATIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED  SAMPLE REQUIREMENTS:  BAMPLE R	REASON FOR REFERRAL/ CLINICAL INDICATION	TEST REQUEST SAMPLE REQUIRED
Clinical genetics approval		
Biochemical genetics   Blood EDTA    Microarray (may require clinical genetics approval)   Blood LiHep + EDTA    Developmental delay   Blood LiHep + EDTA    Chromosomes/karyotype   Crowding QF-PCR    Is the patient pregnant? Y   N   Prenatal diagnosis   CVS/AF (please circle)    SAMPLING DETAILS   Prenatal diagnosis   CVS/AF (please circle)    SAMPLING DETAILS   Diese   Diese   POC/ Issue/ tumour/ FFPE Issue/ Oragene/ buccal smear (please circle and then detail test required below)    SPECIMEN CONTAINER MUST BE LABELLED WITH TWO PATIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED    SPECIMEN CONTAINER MUST BE LABELLED WITH TWO PATIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED    SAMPLE REQUIREMENTS:  EDTA and Lithlum Hoparin blood: 5ml adults/children, 1ml neonates (EDTA), 2ml neonates (LiHep). Invert tubes several times to prevent clotting. Anniolist (bild (AF): too separate sterile universal tubes, 15ml for culture plus 5ml for QF-PCR (samples for QF-PCR must arrive before 2pmi). Chorlonic villi (CVS): 10-30mg in sterile transport media (samples for QF-PCR must arrive before 2pmi). Transport media available from laboratory. Solid dissue; place specimen in a sterile universal tube containing 20ml of transport media. Products of conception (POC): place in a dry, sterile vell sealed container. Transport media available from laboratory. Fluative (e.g. formalin) should NOT be added to any tissue, POC or tumour specimens. Transport media available from laboratory in a blochazard bag, preventing paperwork containing tion in the event of a leakage. All the same and referral card should be assed sealed separately in a blochazard bag, preventing paperwork containing tion in the event of a leakage. All the policy in the containing tion in the event of a leakage. All the policy in the containing tion in the event of a leakage. All the policy in the containing tion in the event of a leaka	Is there a family history (if yes, give details)? Y N	
Microarray (may require clinical genetics approval)   Blood LiHep + EDTA		DNA extraction and storage   Blood EDTA
Developmental delay		Biochemical genetics
Chromosomes/karyotype   Blood LiHep + EDTA		
Is the patient pregnant? Y   N		Developmental delay Blood LiHep + EDTA
If yes, how many weeks gestation?		
If yes, how many weeks gestation?	Is the nationt prognant? V N N	Prenatal diagnosis
SAMPLING DETAILS  Taken by: Bleep: Date: Time:  HIGH RISK URGENT SHIPE LABELLED WITH TWO PATIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED  SPECIMEN CONTAINER MUST BE LABELLED WITH TWO PATIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED  SAMPLE REQUIREMENTS:  EDTA and Lithium Hoparin blood: Sml adults/children, 1ml neonates (EDTA), 2ml neonates (LiHep). Invert tubes several times to prevent clotting. Amniotic fluid (AF): two separate sterile universal tubes, 15ml for culture plus 5ml for QF-PCR (samples for QF-PCR must arrive before 2pm). Chorolonic will (CVS): 10-30mg in sterile transport media (samples for QF-PCR must arrive before 2pm). Solid tissue: place specimen in a sterile universal tube containing 20ml of transport media. Products of conception (POC): place in a dry, sterile well sealed container. Tumour and lymph nodes: should arrive in the laboratory before 4pm, if likely to arrive after this time please contact the laboratory. Flustive (e.g. formalin) should NOT be added to any tissue, POC or tumour specimens. Transport media available from laboratory.  The sample and referral card should be sealed separately in a blohazard bag, preventing paperwork contamination in the event of a leakage. All		
Taken by:  Bleep:  Date:  Time:  HIGH RISK  URGENT  POC/ tissue/ tumour/ FFPE tissue/ Oragene/ buccal smear (please circle and then detail test required below)  SPECIMEN CONTAINER MUST BE LABELLED WITH TWO PATIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED  **SAMPLE REQUIREMENTS:  EDTA and Lithium Heparin blood: Smi aduits/children, 1ml neonates (EDTA), 2ml neonates (LiHep). Invert tubes several times to prevent clotting. Amniotic fluid (AF): two separate sterile universal tubes, 15ml for culture plus 5ml for QF-PCR (samples for QF-PCR must arrive before 2pm). Chorlonic villi (CVS): 10-30mg in sterile transport media (samples for QF-PCR must arrive before 2pm). Transport media available from laboratory. Solid tissue: place specimen in a sterile universal tube containing 20ml of transport media. Products of conception (POC): place in a dry, sterile well sealed container. Tumour and lymph nodes: should arrive in the laboratory before 4pm, if likely to arrive after this time please contact the laboratory. Fixative (e.g. formalin) should NOT be added to any tissue, POC or tumour specimens. Transport media available from laboratory.  The sample and referral card should be sealed separately in a blohazard bag, preventing paperwork contamination in the event of a leakage. All	in year, north many meets gestation:	
Date: Time:  HIGH RISK URGENT URGENT URGENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED  SPECIMEN CONTAINER MUST BE LABELLED WITH TWO PATIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED  SAMPLE REQUIREMENTS:  EDTA and Lithium Hoparin blood: Smi adults/children, 1ml neonates (EDTA), 2ml neonates (LiHep). Invert tubes several times to prevent clotting. Amniotic fluid (AF): two separate sterile universal tubes, 15ml for culture plus 5ml for QF-PCR (samples for QF-PCR must arrive before 2pm). Charolonic will (CVS): 10-30mg in sterile transport media (samples for QF-PCR must arrive before 2pm). Transport media available from laboratory. Solid tissue: place specimen in a sterile universal tube containing 20ml of transport media. Products of conception (POC): place in a dry, sterile well sealed container. Tumour and lymph nodes: should arrive in the laboratory before 4pm, if likely to arrive after this time please contact the laboratory. Fixative (e.g. formalin) should NOT be added to any tissue, POC or tumour specimens. Transport media available from laboratory.  The sample and referral card should be sealed separately in a blohazard bag, preventing paperwork contamination in the event of a leakage. All	SAMPLING DETAILS	OTHER TEST REQUEST/ SAMPLE TYPE
Date: Time:  HIGH RISK	Taken by: Bleep:	
SPECIMEN CONTAINER MUST BE LABELLED WITH TWO PATIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED  8 AMPLE REQUIREMENTS:  EDTA and Lithium Hoparin blood: Sml adults/children, 1ml neonates (EDTA), 2ml neonates (LiHep), invert tubes several times to prevent clotting.  Amniotic fluid (AF): two separate sterile universal tubes, 15ml for culture plus 5ml for QF-PCR was price of QF-PCR must arrive before 2pm).  Chordrolae will (CVS): 10-30mg in 1 sterile transport media (2ml of transport media 2pm), Transport media available from laboratory.  Solid tissue: place specimen in a sterile universal tube containing 20ml of transport media. Products of conception (POC): place in a dry, sterile well sealed container. Tumour and lymph nodes: should arrive in the laboratory before 4pm, if likely to arrive after this time please contact the laboratory. Flustive (e.g. formalin) should NOT be added to any tissue, POC or tumour specimens. Transport media available from laboratory.  The sample and referral card should be sealed separately in a blohazard bag, preventing paperwork contamination in the event of a leakage. All	Date: Time:	(please circle and then detail test required below)
SAMPLE REQUIREMENTS:  EDTA and Lithium Hoparin blood: Smi adults/children, 1mi neonates (EDTA), 2mi neonates (LiHep). Invert tubes several times to prevent clotting.  Amniotic fluid (AF): two separate sterile universal tubes, 15mi for culture plus 5mi for QF-PCR (samples for QF-PCR must arrive before 2pm).  Chorlonio villi (CVS): 10-30mg in sterile transport media (samples for QF-PCR must arrive before 2pm). Transport media available from laboratory.  Solid dissue: place specimen in a sterile universal tube containing 20mi of transport media. Products of conception (POC): place in a dry, sterile well sealed container. Turnour and lymph nodes: should arrive in the laboratory before 4pm, if likely to arrive after this time please contact the laboratory. Fixative (e.g. formalin) should NOT be added to any tissue, POC or tumour specimens. Transport media available from laboratory.  The sample and referral card should be sealed separately in a blohazard bag, preventing paperwork contamination in the event of a leakage. All	HIGH RISK ☐ URGENT ☐	
EDTA and Lithium Heparin blood: Smi adults/children, 1ml neonates (EDTA), 2ml neonates (LiHep). Invert tubes several times to prevent clotting.  Anniotic fluid (AF): two separate sterile universal tubes, 15ml for culture pilus 5ml for QF-PCR (samples for QF-PCR must arrive before 2pm).  Chorlonic viiii (CVS): 10-30mg in sterile transport media (samples for QF-PCR must arrive before 2pm). Transport media available from laboratory.  Solid tissue: place specimen in a sterile universal tube containing 20ml of transport media. Products of conception (POC): place in a dry, sterile well sealed container. Tumour and lymph nodes: should arrive in the laboratory before 4pm, if likely to arrive after this time please contact the laboratory. Fixative (e.g. formalin) should NOT be added to any tissue, POC or tumour specimens. Transport media available from laboratory.  The sample and referral card should be sealed separately in a biohazard bag, preventing paperwork contamination in the event of a leakage. All	SPECIMEN CONTAINER MUST BE LABELLED WITH TWO PA	TIENT IDENTIFIERS, OR SPECIMEN WILL BE REJECTED
packaging must conform to UN3373(P650) standards. If a specimen is known to present an infection risk, please tick the HIGH RISK box above.		
For laboratory use only: Checks:	For laboratory use only:	Checks:

Page 1of 1. Document No MOL289 Revision: 1 Issue date 27.04.12 Approved: NW

This form is available from the EPAS department, Scan department or Perinatal Midwives

#### References

Recurrent Miscarriage, Investigation and Treatment of Couples (Green-top Guideline No. 17), RCOG press, 2011

<u>Clin Appl Thromb Hemost.</u> 2016 Oct 30. pii: 1076029616675967.**The Prevalence of Thrombophilia in Women With Recurrent Fetal Loss and Outcome of Anticoagulation Therapy for the Prevention of <b>Miscarriages.** Nahas R<sup>1</sup>, Saliba W<sup>2</sup>, Elias A<sup>3</sup>, Elias M<sup>4</sup>.

Womens Health (Lond). 2016 Jul;12(4):433-41. doi: 10.1177/1745505716653702. Management of inherited thrombophilia in pregnancy. Ormesher L<sup>1</sup>, Simcox L<sup>2</sup>, Tower C<sup>2</sup>, Greer IA<sup>3</sup>.

Maternal Subclinical Hypothyroidism, Thyroid Autoimmunity, and the Risk of Miscarriage: A Prospective Cohort Study Haixia Liu,1,,2 Zhongyan Shan, Chenyan Li,1 Jinyuan Mao,1 Xiaochen Xie,1 Weiwei Wang,1 Chenling Fan,1 Hong Wang,1 Hongmei Zhang,1 Cheng Han,1 Xinyi Wang,1 Xin Liu,1 Yuxin Fan,1 Suqing Bao,1 and Weiping Teng Thyroid. 2014 Nov 1; 24(11): 1642–1649.

J Pregnancy. 2015;2015:132718. doi: 10.1155/2015/132718. Epub 2015 Aug 17. Impaired Fertility Associated with Subclinical Hypothyroidism and Thyroid Autoimmunity: The Danish General Suburban Population Study. Feldthusen AD1, Pedersen PL2, Larsen J3, Toft Kristensen T4, Ellervik C5, Kvetny J6.

J Gynecol Obstet Biol Reprod (Paris). 2014 Dec;43(10):812-41. doi: 10.1016/j.jgyn.2014.09.014. Epub 2014 Nov 6. [Early recurrent miscarriage: Evaluation and management]. [Article in French] Gallot V1, Nedellec S2, Capmas P3, Legendre G4, Lejeune-Saada V5, Subtil D6, Nizard J7, Levêque J8, Deffieux X2, Hervé B9, Vialard F9.

BMJ. 2014 Oct 6;349:g4929. doi: 10.1136/bmj.g4929. Diagnosis and management of subclinical hypothyroidism in pregnancy. Negro R1, Stagnaro-Green A2.

Hogge WA, Byrnes AL, Lanasa MC, Surti U. The clinical use of karyotyping spontaneous abortions. Am J Obstet Gynecol 2003;189:397–400.

Originator: Dr S Maharaj, K Macpherson

Date Written: July 2017

Ratified: Maternity Clinical Effectiveness Subgroup

**Review Date:** July 2020

This Guideline is currently being reviewed by the Maternity Clinical Effectiveness Group in regard to any changes. It remains a current guideline until the updated version is published.